A biopharma industry leader with potential candidates in a phase III trial for neurological and cardiovascular diseases was interested in making a pricing decision. The engagement included understanding competitor drug positioning along with efficacy study analysis to provide better insights on price points for clients.
Client Background:
The client is one of the key players in the biopharmaceutical domain and developing drugs to treat diseases related to neurological and cardiovascular diseases. The client is a potential candidate in Phase III trials for Alzheimer’s treatment.
Engagement Objective:
The objectives of the study involved engaging KOLs to generate pricing dynamics for Alzheimer’s for further treatment phase
- To communicate about a new drug that is in the approval and pricing decision phase
- To collect insights from KOLs on drug characteristics, feasibility, indicative pricing, and suggestions based on shared clinical trial results
Client Impact:
This study generated several technical and business insights. The final report presented valuable insights on drug advantages, points of concern, expected output/ value, feasibility (technical, regulatory, and financial), indicative pricing, and suggestions.
